Stockreport

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals, Ltd. - American Depositary Shares  (QNRX) 
PDF QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) [Read more]